Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: Subset analyses of the AVAGAST study and the ToGA study

Kensei Yamaguchi, Akira Sawaki, Toshihiko Doi, Taroh Satoh, Yasuhide Yamada, Yasushi Omuro, Tomohiro Nishina, Narikazu Boku, Keisho Chin, Yasuo Hamamoto, Hiroya Takiuchi, Yoshito Komatsu, Shigehira Saji, Wasaburo Koizumi, Yoshinori Miyata, Atsushi Sato, Eishi Baba, Takao Tamura, Takashi Abe, Atsushi Ohtsu

研究成果: ジャーナルへの寄稿記事

24 引用 (Scopus)

抄録

Background: Capecitabine plus cisplatin (XP) is recognized as one of the global standard first-line chemotherapy regimens for patients with metastatic gastric cancer (mGC). Recent multinational phase III trials in mGC have been conducted with XP as the control arm, although no data on XP in Japanese patients with mGC have been published to date. The AVAGAST (XP ± bevacizumab in mGC) and ToGA (XP ± trastuzumab in human epidermal growth factor receptor 2 [HER2]-positive mGC) studies were the first two global studies including Japanese mGC patients. The aim of this analysis was to investigate the efficacy and safety of XP in Japanese mGC patients, using AVAGAST and ToGA subgroup data. Methods: Efficacy and safety analyses were carried out in Japanese patients with mGC receiving XP alone, based on results from the AVAGAST and ToGA studies. There were differences in the target populations between the two studies; for example, the ToGA study limited patients to those with HER2-positive tumors; therefore, efficacy was evaluated separately. Results: Ninety-four Japanese patients in the AVAGAST study and 50 in the ToGA study received XP alone. Median overall and progression-free survivals were 14.2 and 5.7 months, respectively, in the AVAGAST study, and 17.7 and 5.6 months, respectively, in the ToGA study. Overall response rates were 49.2 % in the AVAGAST and 58.5 % in the ToGA study. Adverse events were generally mild; the most common grade 3/4 events were neutropenia, anemia, anorexia, and nausea. Conclusions: XP is effective and well tolerated in Japanese patients with mGC, and could be one of the standard regimens for the first-line treatment in this cohort.

元の言語英語
ページ(範囲)175-182
ページ数8
ジャーナルGastric Cancer
16
発行部数2
DOI
出版物ステータス出版済み - 4 2013

Fingerprint

Cisplatin
Stomach Neoplasms
Safety
Capecitabine
Health Services Needs and Demand
Anorexia
Neutropenia
Nausea
Disease-Free Survival
Anemia
Drug Therapy
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Gastroenterology
  • Cancer Research

これを引用

Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer : Subset analyses of the AVAGAST study and the ToGA study. / Yamaguchi, Kensei; Sawaki, Akira; Doi, Toshihiko; Satoh, Taroh; Yamada, Yasuhide; Omuro, Yasushi; Nishina, Tomohiro; Boku, Narikazu; Chin, Keisho; Hamamoto, Yasuo; Takiuchi, Hiroya; Komatsu, Yoshito; Saji, Shigehira; Koizumi, Wasaburo; Miyata, Yoshinori; Sato, Atsushi; Baba, Eishi; Tamura, Takao; Abe, Takashi; Ohtsu, Atsushi.

:: Gastric Cancer, 巻 16, 番号 2, 04.2013, p. 175-182.

研究成果: ジャーナルへの寄稿記事

Yamaguchi, K, Sawaki, A, Doi, T, Satoh, T, Yamada, Y, Omuro, Y, Nishina, T, Boku, N, Chin, K, Hamamoto, Y, Takiuchi, H, Komatsu, Y, Saji, S, Koizumi, W, Miyata, Y, Sato, A, Baba, E, Tamura, T, Abe, T & Ohtsu, A 2013, 'Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: Subset analyses of the AVAGAST study and the ToGA study', Gastric Cancer, 巻. 16, 番号 2, pp. 175-182. https://doi.org/10.1007/s10120-012-0167-0
Yamaguchi, Kensei ; Sawaki, Akira ; Doi, Toshihiko ; Satoh, Taroh ; Yamada, Yasuhide ; Omuro, Yasushi ; Nishina, Tomohiro ; Boku, Narikazu ; Chin, Keisho ; Hamamoto, Yasuo ; Takiuchi, Hiroya ; Komatsu, Yoshito ; Saji, Shigehira ; Koizumi, Wasaburo ; Miyata, Yoshinori ; Sato, Atsushi ; Baba, Eishi ; Tamura, Takao ; Abe, Takashi ; Ohtsu, Atsushi. / Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer : Subset analyses of the AVAGAST study and the ToGA study. :: Gastric Cancer. 2013 ; 巻 16, 番号 2. pp. 175-182.
@article{55235ccec63f407c9a56dd2adb91c2c1,
title = "Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: Subset analyses of the AVAGAST study and the ToGA study",
abstract = "Background: Capecitabine plus cisplatin (XP) is recognized as one of the global standard first-line chemotherapy regimens for patients with metastatic gastric cancer (mGC). Recent multinational phase III trials in mGC have been conducted with XP as the control arm, although no data on XP in Japanese patients with mGC have been published to date. The AVAGAST (XP ± bevacizumab in mGC) and ToGA (XP ± trastuzumab in human epidermal growth factor receptor 2 [HER2]-positive mGC) studies were the first two global studies including Japanese mGC patients. The aim of this analysis was to investigate the efficacy and safety of XP in Japanese mGC patients, using AVAGAST and ToGA subgroup data. Methods: Efficacy and safety analyses were carried out in Japanese patients with mGC receiving XP alone, based on results from the AVAGAST and ToGA studies. There were differences in the target populations between the two studies; for example, the ToGA study limited patients to those with HER2-positive tumors; therefore, efficacy was evaluated separately. Results: Ninety-four Japanese patients in the AVAGAST study and 50 in the ToGA study received XP alone. Median overall and progression-free survivals were 14.2 and 5.7 months, respectively, in the AVAGAST study, and 17.7 and 5.6 months, respectively, in the ToGA study. Overall response rates were 49.2 {\%} in the AVAGAST and 58.5 {\%} in the ToGA study. Adverse events were generally mild; the most common grade 3/4 events were neutropenia, anemia, anorexia, and nausea. Conclusions: XP is effective and well tolerated in Japanese patients with mGC, and could be one of the standard regimens for the first-line treatment in this cohort.",
author = "Kensei Yamaguchi and Akira Sawaki and Toshihiko Doi and Taroh Satoh and Yasuhide Yamada and Yasushi Omuro and Tomohiro Nishina and Narikazu Boku and Keisho Chin and Yasuo Hamamoto and Hiroya Takiuchi and Yoshito Komatsu and Shigehira Saji and Wasaburo Koizumi and Yoshinori Miyata and Atsushi Sato and Eishi Baba and Takao Tamura and Takashi Abe and Atsushi Ohtsu",
year = "2013",
month = "4",
doi = "10.1007/s10120-012-0167-0",
language = "English",
volume = "16",
pages = "175--182",
journal = "Gastric Cancer",
issn = "1436-3291",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer

T2 - Subset analyses of the AVAGAST study and the ToGA study

AU - Yamaguchi, Kensei

AU - Sawaki, Akira

AU - Doi, Toshihiko

AU - Satoh, Taroh

AU - Yamada, Yasuhide

AU - Omuro, Yasushi

AU - Nishina, Tomohiro

AU - Boku, Narikazu

AU - Chin, Keisho

AU - Hamamoto, Yasuo

AU - Takiuchi, Hiroya

AU - Komatsu, Yoshito

AU - Saji, Shigehira

AU - Koizumi, Wasaburo

AU - Miyata, Yoshinori

AU - Sato, Atsushi

AU - Baba, Eishi

AU - Tamura, Takao

AU - Abe, Takashi

AU - Ohtsu, Atsushi

PY - 2013/4

Y1 - 2013/4

N2 - Background: Capecitabine plus cisplatin (XP) is recognized as one of the global standard first-line chemotherapy regimens for patients with metastatic gastric cancer (mGC). Recent multinational phase III trials in mGC have been conducted with XP as the control arm, although no data on XP in Japanese patients with mGC have been published to date. The AVAGAST (XP ± bevacizumab in mGC) and ToGA (XP ± trastuzumab in human epidermal growth factor receptor 2 [HER2]-positive mGC) studies were the first two global studies including Japanese mGC patients. The aim of this analysis was to investigate the efficacy and safety of XP in Japanese mGC patients, using AVAGAST and ToGA subgroup data. Methods: Efficacy and safety analyses were carried out in Japanese patients with mGC receiving XP alone, based on results from the AVAGAST and ToGA studies. There were differences in the target populations between the two studies; for example, the ToGA study limited patients to those with HER2-positive tumors; therefore, efficacy was evaluated separately. Results: Ninety-four Japanese patients in the AVAGAST study and 50 in the ToGA study received XP alone. Median overall and progression-free survivals were 14.2 and 5.7 months, respectively, in the AVAGAST study, and 17.7 and 5.6 months, respectively, in the ToGA study. Overall response rates were 49.2 % in the AVAGAST and 58.5 % in the ToGA study. Adverse events were generally mild; the most common grade 3/4 events were neutropenia, anemia, anorexia, and nausea. Conclusions: XP is effective and well tolerated in Japanese patients with mGC, and could be one of the standard regimens for the first-line treatment in this cohort.

AB - Background: Capecitabine plus cisplatin (XP) is recognized as one of the global standard first-line chemotherapy regimens for patients with metastatic gastric cancer (mGC). Recent multinational phase III trials in mGC have been conducted with XP as the control arm, although no data on XP in Japanese patients with mGC have been published to date. The AVAGAST (XP ± bevacizumab in mGC) and ToGA (XP ± trastuzumab in human epidermal growth factor receptor 2 [HER2]-positive mGC) studies were the first two global studies including Japanese mGC patients. The aim of this analysis was to investigate the efficacy and safety of XP in Japanese mGC patients, using AVAGAST and ToGA subgroup data. Methods: Efficacy and safety analyses were carried out in Japanese patients with mGC receiving XP alone, based on results from the AVAGAST and ToGA studies. There were differences in the target populations between the two studies; for example, the ToGA study limited patients to those with HER2-positive tumors; therefore, efficacy was evaluated separately. Results: Ninety-four Japanese patients in the AVAGAST study and 50 in the ToGA study received XP alone. Median overall and progression-free survivals were 14.2 and 5.7 months, respectively, in the AVAGAST study, and 17.7 and 5.6 months, respectively, in the ToGA study. Overall response rates were 49.2 % in the AVAGAST and 58.5 % in the ToGA study. Adverse events were generally mild; the most common grade 3/4 events were neutropenia, anemia, anorexia, and nausea. Conclusions: XP is effective and well tolerated in Japanese patients with mGC, and could be one of the standard regimens for the first-line treatment in this cohort.

UR - http://www.scopus.com/inward/record.url?scp=84880702423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880702423&partnerID=8YFLogxK

U2 - 10.1007/s10120-012-0167-0

DO - 10.1007/s10120-012-0167-0

M3 - Article

C2 - 22782463

AN - SCOPUS:84880702423

VL - 16

SP - 175

EP - 182

JO - Gastric Cancer

JF - Gastric Cancer

SN - 1436-3291

IS - 2

ER -